Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: Comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 1, 1998, Pages 114-120

  Chodosh, S ^a,d   Lakshminarayan, S ^a   Swarz, H ^b   Breisch, S ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Intl Pharmaceutical Consult Inc   (United States)

^c Otsuka Pharmaceuticals   (United States)

^d VA Outpatient Clinic Boston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GREPAFLOXACIN; THEOPHYLLINE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; VERTIGO; VOMITING;

EID: 0031982996     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.1.114     Document Type: Article

References (32)

1. Appelbaum, P. C. 1992. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin. Infect. Dis. 15:77-83.
2. Ball, P. 1995. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 108(Suppl.):43-52.
3. Baquero, F., and E. Loza. 1994. Antibiotic resistance of microorganisms involved in ear, nose, and throat infections. Pediatr. Infect. Dis. J. 13(Suppl. 1):9-14.
4. Barry, A. L. 1992. In vitro activities of OPC-17116 and five other fluoroquinolones, abstr. 779, p. 240. In Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. Bartlett, J. G., K. J. Ryan, T. F. Smith, and W. R. Wilson. 1987. Cumitech 7A, Laboratory diagnosis of lower respiratory tract infections, Coordinating ed., J. A. Washington II. American Society for Microbiology, Washington, D.C.
6. Block, S., J. Hendrick, P. Wright, R. Finger, R. Leggiadro, M. Appleton, et al. 1993. Drug-resistant Streptococcus pneumoniae - Kentucky and Tennessee. Morbid. Mortal. Weekly Rep. 43:23-25.
7. Chodosh, S. 1987. Acute bacterial exacerbations in bronchitis and asthma. Am. J. Med. 82(Suppl. 4A):154-163.
8. Chodosh, S. 1991. Use of quinolones for the treatment of acute exacerbations of chronic bronchitis. Am. J. Med. 91(Suppl. 6A):93S-100S.
9. Chodosh, S., J. Tuck, K. D. Stottmeier, and D. Pizzuto. 1989. Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis. Am. J. Med. 87(Suppl. 5A):107S-112S.
10. Cole, P. 1993. Evaluating the clinical outcomes of respiratory infection. Int. J. Antimicrob. Agents 3:S15-S19.
11. Cook, P. J., J. M. Andrews, R. Wise, D. Honeybourne, and H. Moudgil. 1995. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J. Antimicrob. Chemother. 35:317-326.
12. Davies, B. I., F. P. V. Maesen, and C. Baur. 1986. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur. J. Clin. Microbiol. 5:226-231.
13. Doern, G. V., A. Brueggemann, H. P. Holley, Jr., and A. M. Rauch. 1996. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30 center national surveillance study. Antimicrob. Agents Chemother. 40:1208-1213.
14. Efthymiopoulos, C., S. L. Bramer, and A. Maroli. Pharmacokenetics of grepafloxacin after oral administration of single and repeat doses in healthy young males. Clin. Pharm. 33(Suppl. 1):1-8.
15. Eisen, S. A., D. K. Miller, R. S. Woodward, et al. 1990. The effect of prescribed daily dose frequency on patient medication compliance. Arch. Intern. Med. 150:1881-1884.
16. Fuchs, P. C., A. L. Barry, and A. D. Brown. 1996. Tentative interpretive criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones. Diagn. Microbiol. Infect. Dis. 26:23-27.
17. Henry, D., G. E. Ruoff, J. Rhudy, A. Puopolo, M. Drehobl, J. Schoenberger, G. Giguere, and J. J. Collins. 1995. Effectiveness of short-course therapy (5 days) with cefuroxime axetil in treatment of secondary bacterial infections of acute bronchitis. Antimicrob. Agents Chemother. 39:2528-2534.
18. Imada, T., S. Miyazaki, M. Nishida, K. Yamaguchi, and S. Goto. 1992. In vitro and in vivo antibacterial activities of a new quinolone. OPC-17116. Antimicrob. Agents Chemother. 36:573-579.
19. Johnson, J. A. 1995. Pathogenesis of bacterial infections of the respiratory tract. Br. J. Biomed. Sci. 52:157-161.
20. Kenny, G. E., and F. D. Cartwright. 1993. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC17116. Antimicrob. Agents Chemother. 37:1726-1727.
21. Marco, F., R. N. Jones, D. J. Hoban, A. C. Pignatari, N. Yamane, and R. Frei. 1994. In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study. J. Antimicrob. Chemother. 33:647-654.
22. National Committee for Clinical Laboratory Standards. 1994. Performance standards for antimicrobial susceptibility testing, 5th informational supplement, document M100-S5. National Committee for Clinical Laboratory Standards, Villanova, Pa.
23. National Committee for Clinical Laboratory Standards. 1995. Performance standards for antimicrobial susceptibility testing. 6th informational supplement, document M100-S6. National Committee for Clinical Laboratory Standards, Villanova, Pa.
24. Neu, H. C., W. Fang, J.-W. Gu, and N.-X. Chin. 1992. In vitro activity of OP-17116 Antimicrob. Agents Chemother. 36:1310-1315.
25. Notario, G., N. Siepman, K. Devcich, and D. R. P. Guay. 1993. Comparative safety and efficacy of clarithromycin and three oral cephalosporins in the treatment of outpatients with bacterial bronchitis. Curr. Ther. Res. 54:628-640.
26. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1995. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J. Antimicrob. Chemother. 35:230-232.
27. Paton, J. H., and D. S. Reeves. 1992. Adverse reactions to the fluoroquinolones. Adv. Drug React. Bull. 153:575-578.
28. Sader, H. S., M. E. Erwin, and R. N. Jones. 1992. In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones. Eur. J. Clin. Microbiol. Infect. Dis. 11:372-381.
29. Sewell, D. L., and A. L. Barry. 1995. Tentative criteria for determining the in vitro susceptibilities of Haemophilus influenzae, including quality control parameters to two fluoroquinolones (grepafloxacin and PD 131628). Diagn. Microbiol. Infect. Dis. 21:175-179.
30. Skudlarska, B. A., and G. C. Scott. 1992. The role of antibiotics in the management of acute exacerbations of chronic bronchitis (answers to some commonly asked questions). Mol. Med. 89:289-293.
31. Spangler, S. K., M. R. Jacobs, G. A. Pankuch, and P. C. Appelbaum. 1993. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9429 and RP 67829. J. Antimicrob. Chemother. 31:273-280.
32. Wise, R., J. M. Andrews, and N. Brenwald. 1993. The in vitro activities of OPC-17116, a new 5-methyl substituted quinolone. J. Antimicrob. Chemother. 31:487-504.